@article {Nadeau2020.10.14.20212621, author = {Sarah Nadeau and Christiane Beckmann and Ivan Topolsky and Timothy Vaughan and Emma Hodcroft and Tobias Sch{\"a}r and Ina Nissen and Natascha Santacroce and Elodie Burcklen and Pedro Ferreira and Kim Philipp Jablonski and Susana Posada-C{\'e}spedes and Vincenzo Capece and Sophie Seidel and Noemi Santamaria de Souza and Julia M. Martinez-Gomez and Phil Cheng and Philipp P. Bosshard and Mitchell P. Levesque and Verena Kufner and Stefan Schmutz and Maryam Zaheri and Michael Huber and Alexandra Trkola and Samuel Cordey and Florian Laubscher and Ana Rita Gon{\c c}alves and Karoline Leuzinger and Madlen Stange and Alfredo Mari and Tim Roloff and Helena Seth-Smith and Hans H. Hirsch and Adrian Egli and Maurice Redondo and Olivier Kobel and Christoph Noppen and Niko Beerenwinkel and Richard A. Neher and Christian Beisel and Tanja Stadler}, title = {Quantifying SARS-CoV-2 spread in Switzerland based on genomic sequencing data}, elocation-id = {2020.10.14.20212621}, year = {2020}, doi = {10.1101/2020.10.14.20212621}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Pathogen genomes provide insights into their evolution and epidemic spread. We sequenced 1,439 SARS-CoV-2 genomes from Switzerland, representing 3-7\% of all confirmed cases per week. Using these data, we demonstrate that no one lineage became dominant, pointing against evolution towards general lower virulence. On an epidemiological level, we report no evidence of cryptic transmission before the first confirmed case. We find many early viral introductions from Germany, France, and Italy and many recent introductions from Germany and France. Over the summer, we quantify the number of non-traceable infections stemming from introductions, quantify the effective reproductive number, and estimate the degree of undersampling. Our framework can be applied to quantify evolution and epidemiology in other locations or for other pathogens based on genomic data.One Sentence Summary We quantify SARS-CoV-2 spread in Switzerland based on genome sequences from our nation-wide sequencing effort.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSN and TS are supported by the Swiss National Science Foundation (grant number 31CA30_196267).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data used is available on https://www.gisaid.org/.}, URL = {https://www.medrxiv.org/content/early/2020/10/30/2020.10.14.20212621}, eprint = {https://www.medrxiv.org/content/early/2020/10/30/2020.10.14.20212621.full.pdf}, journal = {medRxiv} }